Business Description
Immix Biopharma is a US-based clinical-stage company focused on developing advanced cell therapies for serious blood disorders and immune system diseases, operating across both the United States and Australia. Its leading treatment, NXC-201, targets a rare and life-threatening protein disorder called AL Amyloidosis in patients who have not responded to prior treatments. The company also works with BeiGene Ltd. to test a combination therapy against solid tumors. Founded in 2012 and based in Los Angeles, Immix Biopharma continues to build its pipeline of specialized treatments.
